| Date | Title | Description |
| 03.01.2019 | NEA Joins $31M Series A for Tiburio Therapeutics | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan today announced the launch of Tiburio Therapeutics Inc. (Tiburio), a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases. Tib... |
| 09.04.2018 | NEA-backed Cydan Appoints Imran A. Babar Chief Business Officer | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan today announced that Imran A. Babar, PhD, has been named to the leadership team as chief business officer to help the company advance new and innovative therapies for patients living with rare monoge... |
| 18.10.2017 | Term Sheet — Wednesday, October 18 | 5 Qs WITH A DEALMAKER
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
In the Valley, Jordan is also known for mentoring investors with non-tech backgrounds. One examples is Golden State W... |
| 17.10.2017 | Cydan Secures $34M |
CAMBRIDGE, MA, Cydan, an orphan drug accelerator, has raised $34 million in funding.
>> Click here for more funding data on Cydan
>> To export Cydan funding data to PDF and Excel, click here
Cydan today announced a new ro... |
| 17.10.2017 | Cydan Raises $34 Million from NEA | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan today announced a new round of financing, raising a committed total of $34 million to advance the company’s efforts to create new and innovative therapies for patients living with rare genetic diseas... |
| 17.10.2017 | Cydan Raises $34M in Funding | Cydan, a Cambridge, MA-based developer of innovative therapies for patients living with rare genetic diseases, raised $34m in funding.
New investor Longitude Capital joined existing investors New Enterprise Associates (who led the round) al... |
| 03.04.2017 | Cydan Development Announces the Acquisition of Its First Rare Disease Spin-out, Vtesse, Inc. by Sucampo Pharmaceuticals, Inc. | Link to Release
Cambridge, Mass., April 3, 2017 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, today announces that Vtesse, Inc., ... |
| 29.11.2016 | Vtesse Receives Rare Pediatric Disease Designation for VTS-270 for the Treatment of Niemann-Pick Type C1 Disease | Gaithersburg, MD — Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease des... |
| 11.10.2016 | Cydan Announces the Promotion of James McArthur, Ph.D. to President, Research and Development | Cambridge, MA — Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, announced the promotion of James McArthur, Ph.D. to president, research ... |
| 14.04.2016 | Imara Raises $31M in Series A Funding | Imara, Inc., an orphan drug company formed by Cydan Development, a Cambridge, Mass.-based orphan drug accelerator dedicated to creating therapies for people living with rare genetic diseases, raised $31m in a Series A round of funding.
Back... |
| 14.04.2016 | Daily funding roundup - April 14, 2016 | Quartet raised $40M Series B; Imara secured $31M; Vyomo rebranded and received investment;
Yup, formerly known as MathCrunch, has picked up $4 million in seed funding from new and existing investors, including Stanford University's StartX F... |
| 14.04.2016 | Cydan Development Announces Formation of Imara Inc. with $31M Series A Funding to Develop Therapeutic for Sickle Cell Disease | CAMBRIDGE, Mass.–(BUSINESS WIRE)–April 14, 2016–
Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, I... |
| 14.04.2016 | Cydan Raises $31M in Series A Funding | Cambridge, MA — Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc. This is the second orphan dru... |
| 24.06.2015 | Cydan Announces Recipients of Its MassChallenge Scholarship | CAMBRIDGE, Mass.–(BUSINESS WIRE)–June 24, 2015–
Cydan Development, Inc., an orphan drug accelerator that identifies and de-risks programs with significant therapeutic potential, today announced that it has selected Cogentis Therapeutics, HI... |
| 15.06.2015 | Vtesse, Inc. Expands Scientific Advisory Board, Fills Key Patient Advocacy Position | Gaithersburg, MD — Vtesse, Inc., a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today the expansion of its Scientific Advisory Board (SAB) ... |
| 23.02.2015 | Orphan Drug Accelerator Cydan Supports Rare Disease Day® and Joins Patients, Advocates and Massachusetts Legislators to Raise Awareness for Rare Diseases | CAMBRIDGE, Mass.–(BUSINESS WIRE)–February 23, 2015–
Cydan Development, Inc., an orphan drug accelerator that identifies and de-risks programs with significant therapeutic potential, will join forces with rare disease patients, caregivers an... |
| 07.01.2015 | Vtesse Raises $25M in Series A Funding | Vtesse, Inc., a Gaithersburg, Maryland-based rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases, raised $25m in Series A funding.
The round was led by New Enterprise Associates (... |
| 15.10.2014 | Orphan Drug Accelerator Cydan Expands Transactional Expertise with Appointment of Vered Bisker-Leib, Ph.D., MBA, as Chief Business Officer | CAMBRIDGE, Mass.–(BUSINESS WIRE)–October 15, 2014–
Cydan Development, Inc., an orphan drug accelerator that identifies and de-risks programs with significant therapeutic and commercial potential, today announced the appointment of Vered Bis... |
| 01.10.2013 | Cydan Raises $10M Funding | Cydan, LLC, a Cambridge, Mass.-based orphan drug accelerator, raised an additional $10m funding.
The round was led by new investors Lundbeckfond Ventures and Bay City Capital, with participation from previous investors New Enterprise Associ... |
| 01.10.2013 | Cydan Expands Initial Financing to $26 Million; Lundbeckfond Ventures and Bay City Capital Join Diverse Investor Syndicate With Participation from NEA and Alexandria Venture Investments | Cambridge, Mass. – October 1, 2013 – Cydan, LLC, an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced that the company has expanded its initial round of financing, bring... |
| 01.10.2013 | Cydan Adds $10M Expanded Round |
CAMBRIDGE, MA, Orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced that the company has expanded its initial round of financing.
>> Click here for more funding da... |
| 11.04.2013 | Cydan Launches with $16M |
CAMBRIDGE, MA, Orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced its launch with $16 million in financing led by New Enterprise Associates.
>> Click here for mo... |
| 11.04.2013 | Cydan Launches with $16M | Cydan, LLC, a Cambridge, Mass.-based orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, has just launched with $16m in financing.
The round was led by New Enterprise Associates (NEA) and... |
